

Thiosulfonylation of alkenes with the insertion of sulfur dioxide under non-metallic conditions

Fu-Sheng He,^a Youqian Wu,^a Jun Zhang,^b Hongguang Xia,^{*a} and Jie Wu^{*b,c}


Supporting Information

1. General experimental methods (S2).
2. General experimental procedure and characterization data (S2-S13).
3. ¹H and ¹³C NMR spectra of compounds **3** (S14-S57).
4. Crystal structure determination of compound **3s** (S58-S59)


General experimental methods:

Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32-63 μm , standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~ 20 Torr at 25-35 $^{\circ}\text{C}$. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a microTOF II Instrument.

General experimental procedure for the reaction of alkenes 1, (DABCO) \cdot (SO₂)₂, and aryldiazonium tetrafluoroborates 2.




1-(2-Allylaryl)thiourea **1** (0.2 mmol) was added to a mixture of aryldiazonium tetrafluoroborate **2** (0.3 mmol) and DABCO \cdot (SO₂)₂ (0.3 mmol) in DCE (2.0 mL) under N₂ atmosphere. The mixture was stirred at room temperature for 12 h. After completion of reaction as indicated by TLC, the solvent was evaporated and the residue was purified directly by flash column chromatography (*n*-hexane/ethyl acetate = 8:1) to give the corresponding product **3**.




N-phenyl-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3a**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, $J = 8.3$ Hz, 2H), 7.68 (d, $J = 7.9$ Hz, 2H), 7.39 (d, $J = 8.0$ Hz, 2H), 7.36 – 7.26 (m, 3H), 7.20 (dd, $J = 7.4, 1.1$ Hz, 1H), 7.10 – 6.97 (m, 3H), 6.87 (brs, 1H), 4.42 – 4.32 (m, 1H), 3.59 (dd, $J = 14.3, 7.8$ Hz, 1H), 3.37 (dd, $J = 14.3, 5.5$ Hz, 1H), 3.20 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.94 (dd, $J = 13.8, 8.1$ Hz, 1H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.2, 145.5, 145.3, 139.9, 136.5, 130.2, 129.7, 129.1, 128.9, 128.2, 128.1, 123.9, 123.5, 123.5, 119.5, 62.1, 49.7, 36.9, 21.7; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 423.1195, found: 423.1179.




N-phenyl-4-((phenylsulfonyl)methyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3b**)

^1H NMR (400 MHz, CDCl_3) δ 7.98 – 7.90 (m, 2H), 7.72 – 7.64 (m, 3H), 7.59 (dd, $J = 10.5, 4.7$ Hz, 2H), 7.35 – 7.25 (m, 3H), 7.19 (dd, $J = 7.4, 1.1$ Hz, 1H), 7.10 – 6.98 (m, 3H), 6.91 (brs, 1H), 4.44 – 4.34 (m, 1H), 3.61 (dd, $J = 14.3, 7.8$ Hz, 1H), 3.39 (dd, $J = 14.2, 5.5$ Hz, 1H), 3.20 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.94 (dd, $J = 13.8, 8.1$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.2, 145.5, 139.9, 139.4, 134.2, 129.7, 129.6, 129.1, 129.0, 128.2, 128.0, 123.9, 123.6, 123.5, 119.5, 62.0, 49.6, 36.9; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 409.1039, found: 409.1020.



4-(((4-Methoxyphenyl)sulfonyl)methyl)-*N*-phenyl-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3c**)


^1H NMR (400 MHz, CDCl_3) δ 7.90 – 7.83 (m, 2H), 7.68 (d, $J = 7.9$ Hz, 2H), 7.36 – 7.26 (m, 3H), 7.24 – 7.17 (m, 1H), 7.11 – 6.98 (m, 5H), 6.83 (brs, 1H), 4.43 – 4.32 (m, 1H), 3.90 (s, 3H), 3.59 (dd, $J = 14.3, 7.7$ Hz, 1H), 3.37 (dd, $J = 14.2, 5.5$ Hz, 1H), 3.21 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.95 (dd, $J = 13.8, 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.1, 148.2, 145.7, 139.9, 130.8, 130.3, 129.7, 129.2, 129.0, 128.2, 123.9, 123.6, 123.5, 119.5, 114.7, 62.3, 55.8, 49.8, 36.9; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_3\text{S}_2^+$ ($\text{M}+\text{H}^+$): 439.1145, found: 439.1139.



4-(((4-(*tert*-Butyl)phenyl)sulfonyl)methyl)-*N*-phenyl-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3d**)


^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 8.6$ Hz, 2H), 7.68 (d, $J = 8.0$ Hz, 2H), 7.64 – 7.57 (m, 2H), 7.36 – 7.26 (m, 3H), 7.24 – 7.17 (m, 1H), 7.11 – 6.97 (m, 3H), 6.87 (brs, 1H), 4.45 – 4.36 (m, 1H), 3.60 (dd, $J = 14.2, 8.0$ Hz, 1H), 3.38 (dd, $J = 14.2, 5.3$ Hz, 1H), 3.23 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.96 (dd, $J = 13.8, 8.0$ Hz, 1H), 1.36 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.3, 148.2, 145.7, 140.0, 136.4, 129.7, 129.2, 129.0, 128.2,

127.9, 126.6, 123.9, 123.6, 123.5, 119.6, 62.0, 49.7, 36.8, 35.4, 31.1; HRMS (ESI) calcd for $C_{26}H_{29}N_2O_2S_2^+$ ($M+H^+$): 465.1665, found: 465.1662.




N-phenyl-4-((*o*-tolylsulfonyl)methyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3e**)

1H NMR (400 MHz, $CDCl_3$) δ 8.04 (dd, $J = 7.9, 1.2$ Hz, 1H), 7.68 (d, $J = 7.8$ Hz, 2H), 7.56 (td, $J = 7.5, 1.3$ Hz, 1H), 7.45 – 7.26 (m, 5H), 7.19 (dd, $J = 7.4, 1.2$ Hz, 1H), 7.12 – 6.97 (m, 3H), 6.81 (brs, 1H), 4.51 – 4.39 (m, 1H), 3.65 (dd, $J = 14.3, 7.9$ Hz, 1H), 3.40 (dd, $J = 14.3, 5.3$ Hz, 1H), 3.20 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.95 (dd, $J = 13.8, 7.9$ Hz, 1H), 2.72 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 148.2, 145.6, 139.9, 138.0, 137.6, 134.2, 133.0, 130.1, 129.7, 129.1, 129.0, 128.2, 127.0, 123.9, 123.6, 123.5, 119.6, 61.0, 49.6, 36.9, 20.5; HRMS (ESI) calcd for $C_{23}H_{23}N_2O_2S_2^+$ ($M+H^+$): 423.1195, found: 423.1162.




N-phenyl-4-((*m*-tolylsulfonyl)methyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3f**)

1H NMR (400 MHz, $CDCl_3$) δ 7.83 – 7.65 (m, 4H), 7.56 – 7.46 (m, 2H), 7.38 – 7.27 (m, 3H), 7.21 (dd, $J = 7.4, 1.2$ Hz, 1H), 7.13 – 6.98 (m, 3H), 6.83 (brs, 1H), 4.46 – 4.35 (m, 1H), 3.61 (dd, $J = 14.2, 7.9$ Hz, 1H), 3.38 (dd, $J = 14.2, 5.2$ Hz, 1H), 3.22 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.96 (dd, $J = 13.8, 8.1$ Hz, 1H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 148.2, 145.5, 140.0, 139.9, 139.2, 135.0, 129.7, 129.4, 129.1, 129.0, 128.3, 128.2, 125.1, 123.9, 123.6, 123.5, 119.5, 62.0, 49.6, 36.9, 21.4; HRMS (ESI) calcd for $C_{23}H_{23}N_2O_2S_2^+$ ($M+H^+$): 423.1195, found: 423.1171.




4-(((4-Chlorophenyl)sulfonyl)methyl)-*N*-phenyl-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3g**)

^1H NMR (400 MHz, CDCl_3) δ 7.91 – 7.83 (m, 2H), 7.67 (d, $J = 7.9$ Hz, 2H), 7.62 – 7.54 (m, 2H), 7.36 – 7.26 (m, 3H), 7.24 – 7.18 (m, 1H), 7.11 – 6.97 (m, 3H), 6.85 (brs, 1H), 4.45 – 4.35 (m, 1H), 3.60 (dd, $J = 14.2, 7.7$ Hz, 1H), 3.38 (dd, $J = 14.2, 5.6$ Hz, 1H), 3.22 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.96 (dd, $J = 13.8, 7.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.0, 145.4, 141.1, 139.9, 137.8, 129.9, 129.7, 129.5, 129.0, 128.3, 123.9, 123.7, 123.6, 119.6, 62.1, 49.4, 36.9; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{20}\text{ClN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 443.0649, found: 443.0629.




4-(((4-Bromophenyl)sulfonyl)methyl)-*N*-phenyl-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3h**)

^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, $J = 8.6$ Hz, 2H), 7.73 (d, $J = 8.7$ Hz, 2H), 7.67 (d, $J = 7.9$ Hz, 2H), 7.38 – 7.26 (m, 3H), 7.21 (d, $J = 7.3$ Hz, 1H), 7.14 – 6.96 (m, 3H), 6.87 (brs, 1H), 4.46 – 4.34 (m, 1H), 3.60 (dd, $J = 14.3, 7.6$ Hz, 1H), 3.38 (dd, $J = 14.2, 5.6$ Hz, 1H), 3.22 (dd, $J = 13.8, 5.1$ Hz, 1H), 2.95 (dd, $J = 13.8, 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.1, 145.4, 139.9, 138.3, 132.9, 129.7, 129.6, 129.0, 128.3, 123.9, 123.7, 123.6, 119.6, 62.1, 49.4, 36.9; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{20}\text{BrN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 487.0131, found: 487.0136.




N-phenyl-4-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3i**)

^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, $J = 8.2$ Hz, 2H), 7.88 (d, $J = 8.2$ Hz, 2H), 7.67 (d, $J = 7.8$ Hz, 2H), 7.38 – 7.27 (m, 3H), 7.23 (dd, $J = 7.5, 1.2$ Hz, 1H), 7.12 – 6.99 (m, 3H), 6.83 (brs, 1H), 4.50 – 4.39 (m, 1H), 3.64 (dd, $J = 14.2, 7.7$ Hz, 1H), 3.41 (dd, $J = 14.2, 5.6$ Hz, 1H), 3.26 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.98 (dd, $J = 13.9, 7.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.1, 145.2, 142.9, 139.8, 135.9 (q, $J = 33.3$ Hz), 129.7, 129.0, 128.8, 128.7, 128.4, 126.7 (q, $J = 3.6$ Hz), 124.0, 123.7, 123.6, 123.0 (q, $J = 273.2$ Hz), 119.5, 61.9, 49.3, 37.0; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{20}\text{F}_3\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 477.0913, found: 477.0899.




4-(((3-Chlorophenyl)sulfonyl)methyl)-*N*-phenyl-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3j**)

^1H NMR (400 MHz, CDCl_3) δ 7.94 (t, $J = 1.8$ Hz, 1H), 7.83 (d, $J = 7.8$ Hz, 1H), 7.76 – 7.62 (m, 3H), 7.55 (t, $J = 7.9$ Hz, 1H), 7.37 – 7.27 (m, 3H), 7.22 (d, $J = 7.4$ Hz, 1H), 7.12 – 6.98 (m, 3H), 6.86 (brs, 1H), 4.47 – 4.36 (m, 1H), 3.62 (dd, $J = 14.2, 7.7$ Hz, 1H), 3.40 (dd, $J = 14.2, 5.6$ Hz, 1H), 3.23 (dd, $J = 13.8, 5.1$ Hz, 1H), 2.97 (dd, $J = 13.8, 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.1, 145.3, 141.1, 139.9, 135.9, 134.4, 130.9, 129.7, 129.0, 128.9, 128.3, 128.1, 126.2, 123.9, 123.7, 123.6, 119.6, 62.0, 49.4, 36.9; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{20}\text{ClN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 443.0649, found: 443.0642.




Ethyl 4-(((2-(phenylamino)-4,5-dihydrobenzo[*d*][1,3]thiazepin-4-yl)methyl)sulfonyl)benzoate (**3k**)

^1H NMR (400 MHz, CDCl_3) δ 8.29 – 8.21 (m, 2H), 8.05 – 7.98 (m, 2H), 7.67 (d, $J = 7.9$ Hz, 2H), 7.36 – 7.27 (m, 3H), 7.24 – 7.18 (m, 1H), 7.12 – 6.97 (m, 3H), 6.82 (brs, 1H), 4.47 – 4.36 (m, 3H), 3.63 (dd, $J = 14.3, 7.7$ Hz, 1H), 3.41 (dd, $J = 14.3, 5.6$ Hz, 1H), 3.22 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.96 (dd, $J = 13.8, 8.0$ Hz, 1H), 1.43 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.8, 148.0, 145.4, 143.0, 139.9, 135.6, 130.6, 129.7, 129.0, 128.9, 128.3, 128.1, 123.9, 123.6, 123.5, 119.6, 62.0, 61.9, 49.4, 36.9, 14.3; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{25}\text{N}_2\text{O}_4\text{S}_2^+$ ($\text{M}+\text{H}^+$): 481.1250, found: 481.1245.




Methyl 3-(((2-(phenylamino)-4,5-dihydrobenzo[*d*][1,3]thiazepin-4-yl)methyl)sulfonyl)benzoate (**3l**)

^1H NMR (400 MHz, CDCl_3) δ 8.60 (t, $J = 1.5$ Hz, 1H), 8.38 – 8.33 (m, 1H), 8.16 – 8.11 (m, 1H), 7.74 – 7.63 (m, 3H), 7.36 – 7.26 (m, 3H), 7.23 (d, $J = 6.6$ Hz, 1H), 7.10 – 6.98 (m, 3H), 6.85 (brs, 1H), 4.47 – 4.37 (m, 1H), 3.98 (s, 3H), 3.64 (dd, $J = 14.2, 7.6$ Hz, 1H), 3.43 (dd, $J = 14.2, 5.6$ Hz, 1H), 3.24 (dd, $J = 13.8, 5.2$ Hz, 1H), 2.97 (dd, $J = 13.8, 8.1$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.1, 148.1, 145.4, 140.1, 139.9, 135.0, 132.0, 131.8, 129.9, 129.7, 129.2, 129.0, 128.3, 123.9, 123.6, 123.5, 119.5, 62.0, 52.8, 49.5, 37.0; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_4\text{S}_2^+$ ($\text{M}+\text{H}^+$): 467.1094, found: 467.1079.




N-(*p*-tolyl)-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3m**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.34 – 7.26 (m, 1H), 7.22 – 7.17 (m, 1H), 7.12 (d, J = 8.2 Hz, 2H), 7.08 – 6.95 (m, 2H), 6.77 (brs, 1H), 4.42 – 4.30 (m, 1H), 3.59 (dd, J = 14.3, 7.9 Hz, 1H), 3.36 (dd, J = 14.2, 5.4 Hz, 1H), 3.20 (dd, J = 13.8, 5.2 Hz, 1H), 2.94 (dd, J = 13.8, 8.0 Hz, 1H), 2.47 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.3, 145.6, 145.3, 137.4, 136.5, 133.1, 130.2, 129.7, 129.4, 129.2, 128.2, 128.1, 123.9, 123.4, 119.7, 62.1, 49.6, 36.9, 21.7, 20.9; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 437.1352, found: 437.1345.




N-(4-methoxyphenyl)-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3n**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.59 (d, J = 8.9 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.30 – 7.24 (m, 1H), 7.22 – 7.17 (m, 1H), 7.06 – 6.94 (m, 2H), 6.91 – 6.82 (m, 2H), 6.71 (brs, 1H), 4.40 – 4.30 (m, 1H), 3.80 (s, 3H), 3.59 (dd, J = 14.3, 7.9 Hz, 1H), 3.36 (dd, J = 14.2, 5.4 Hz, 1H), 3.20 (dd, J = 13.8, 5.2 Hz, 1H), 2.94 (dd, J = 13.8, 8.0 Hz, 1H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.8, 148.3, 145.9, 145.3, 136.4, 133.2, 130.2, 129.7, 129.2, 128.2, 128.1, 123.8, 123.4, 121.4, 114.1, 62.1, 55.5, 49.4, 36.9, 21.7; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_3\text{S}_2^+$ ($\text{M}+\text{H}^+$): 453.1301, found: 453.1296.




N-(4-chlorophenyl)-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3o**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.32 – 7.26 (m, 3H), 7.21 (d, J = 6.5 Hz, 1H), 7.05 (td, J = 7.4, 1.1 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.87 (brs, 1H), 4.44 – 4.33 (m, 1H), 3.59 (dd, J = 14.3, 7.8 Hz, 1H), 3.36 (dd, J = 14.2, 5.5 Hz, 1H), 3.20 (dd, J = 13.9, 5.2 Hz, 1H), 2.95 (dd, J = 13.8, 8.0 Hz, 1H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 147.8, 145.8, 145.4, 138.6, 136.3, 130.2, 129.7, 129.1, 128.9, 128.3, 128.2, 128.0, 123.9, 123.8, 120.8, 62.0, 49.8, 36.8, 21.7; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{22}\text{ClN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 457.0806, found: 457.0790.




N-(4-bromophenyl)-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3p**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.6 Hz, 2H), 7.47 – 7.36 (m, 4H), 7.33 – 7.27 (m, 1H), 7.21 (d, J = 7.3 Hz, 1H), 7.05 (t, J = 7.4 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.85 (brs, 1H), 4.45 – 4.33 (m, 1H), 3.59 (dd, J = 14.2, 7.8 Hz, 1H), 3.36 (dd, J = 14.2, 5.5 Hz, 1H), 3.20 (dd, J = 13.9, 5.1 Hz, 1H), 2.95 (dd, J = 13.8, 8.0 Hz, 1H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 147.8, 145.7, 145.4, 139.1, 136.3, 131.8, 130.2, 129.7, 129.1, 128.3, 128.0, 123.9, 123.8, 121.2, 115.7, 62.0, 49.8, 36.8, 21.7; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{22}\text{BrN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 501.0301, found: 501.0301.




N-(4-nitrophenyl)-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3q**)

^1H NMR (400 MHz, CDCl_3) δ 8.21 (d, $J = 9.1$ Hz, 2H), 7.92 – 7.74 (m, 4H), 7.40 (d, $J = 8.0$ Hz, 2H), 7.33 (td, $J = 7.7, 1.4$ Hz, 1H), 7.24 (d, $J = 7.5$ Hz, 1H), 7.10 (td, $J = 7.4, 0.9$ Hz, 1H), 7.03 (d, $J = 7.7$ Hz, 1H), 4.53 – 4.40 (m, 1H), 3.60 (dd, $J = 14.2, 7.5$ Hz, 1H), 3.38 (dd, $J = 14.2, 5.6$ Hz, 1H), 3.21 (dd, $J = 13.9, 5.0$ Hz, 1H), 2.98 (dd, $J = 13.9, 8.0$ Hz, 1H), 2.48 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 147.2, 145.9, 145.8, 145.6, 142.4, 136.2, 130.3, 129.8, 129.0, 128.4, 128.0, 125.0, 124.3, 124.0, 118.8, 62.1, 50.5, 36.9, 21.7; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_4\text{S}_2^+$ ($\text{M}+\text{H}^+$): 468.1046, found: 468.1032.




4-((Naphthalen-1-ylsulfonyl)methyl)-*N*-phenyl-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3r**)

^1H NMR (400 MHz, CDCl_3) δ 8.73 (d, $J = 8.6$ Hz, 1H), 8.34 (dd, $J = 7.4, 1.2$ Hz, 1H), 8.17 (d, $J = 8.2$ Hz, 1H), 8.02 (d, $J = 8.1$ Hz, 1H), 7.80 – 7.72 (m, 1H), 7.71 – 7.52 (m, 4H), 7.33 – 7.21 (m, 3H), 7.12 (d, $J = 6.5$ Hz, 1H), 7.07 – 6.92 (m, 3H), 6.55 (brs, 1H), 4.46 – 4.34 (m, 1H), 3.78 (dd, $J = 14.4, 7.1$ Hz, 1H), 3.64 (dd, $J = 14.4, 5.9$ Hz, 1H), 3.14 (dd, $J = 13.8, 5.3$ Hz, 1H), 2.88 (dd, $J = 13.7, 8.7$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.2, 145.5, 139.8, 135.8, 134.4, 134.2, 130.9, 129.6, 129.1, 128.9, 128.9, 128.2, 127.3, 124.7, 123.8, 123.6, 123.5, 119.5, 61.7, 50.1, 37.1; HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{23}\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 459.1195, found: 459.1191.




7-Methyl-*N*-phenyl-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3s**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.32 (t, J = 8.0 Hz, 2H), 7.13 – 7.03 (m, 2H), 6.99 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.80 (brs, 1H), 4.40 – 4.30 (m, 1H), 3.60 (dd, J = 14.3, 7.9 Hz, 1H), 3.38 (dd, J = 14.3, 5.4 Hz, 1H), 3.16 (dd, J = 13.8, 5.2 Hz, 1H), 2.89 (dd, J = 13.8, 8.2 Hz, 1H), 2.47 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.4, 145.3, 140.0, 136.5, 133.1, 130.3, 130.2, 128.9, 128.9, 128.1, 123.7, 123.4, 119.5, 62.2, 49.7, 36.9, 21.7, 20.9; HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{23}\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 437.1352, found: 437.1338.




N-(4-bromophenyl)-7-methyl-4-(tosylmethyl)-4,5-dihydrobenzo[*d*][1,3]thiazepin-2-amine (**3t**)

^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.46 – 7.37 (m, 4H), 7.10 (dd, J = 8.0, 1.4 Hz, 1H), 6.99 (s, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.80 (brs, 1H), 4.42 – 4.31 (m, 1H), 3.59 (dd, J = 14.3, 7.8 Hz, 1H), 3.37 (dd, J = 14.3, 5.5 Hz, 1H), 3.15 (dd, J = 13.8, 5.2 Hz, 1H), 2.89 (dd, J = 13.8, 8.1 Hz, 1H), 2.47 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.6, 145.4, 145.1, 139.2, 136.4, 133.3, 131.8, 130.3, 130.2, 128.9, 128.0, 123.7, 121.2, 115.6, 62.2, 49.8, 36.9, 21.7, 20.9; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{24}\text{BrN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 515.0457, found: 515.0471.




N-(4-bromophenyl)-4-(((4-bromophenyl)sulfonyl)methyl)-7-methyl-4,5-dihydrobenzo[d][1,3]thiazepin-2-amine (**3u**)


^1H NMR (400 MHz, CDCl_3) δ 7.85 – 7.69 (m, 4H), 7.56 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.9 Hz, 2H), 7.15 – 7.06 (m, 1H), 7.04 – 6.97 (m, 1H), 6.89 (d, J = 8.0 Hz, 1H), 6.77 (brs, 1H), 4.44 – 4.33 (m, 1H), 3.60 (dd, J = 14.3, 7.6 Hz, 1H), 3.38 (dd, J = 14.2, 5.7 Hz, 1H), 3.17 (dd, J = 13.8, 5.2 Hz, 1H), 2.90 (dd, J = 13.8, 8.0 Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.1, 139.1, 138.3, 133.4, 132.9, 131.88, 131.8, 130.3, 129.7, 129.6, 129.0, 128.7, 123.7, 121.1, 115.7, 62.2, 49.6, 37.0, 20.9; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{21}\text{Br}_2\text{N}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 578.9406, found: 578.9407.





7-Fluoro-*N*-phenyl-4-(tosylmethyl)-4,5-dihydrobenzo[d][1,3]thiazepin-2-amine (**3v**)


^1H NMR (400 MHz, CDCl_3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 7.8 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 7.33 (t, J = 8.0 Hz, 2H), 7.08 (t, J = 7.4 Hz, 1H), 7.01 – 6.91 (m, 3H), 6.83 (brs, 1H), 4.44 – 4.34 (m, 1H), 3.57 (dd, J = 14.2, 8.1 Hz, 1H), 3.36 (dd, J = 14.2, 5.3 Hz, 1H), 3.18 (dd, J = 13.8, 5.2 Hz, 1H), 2.94 (dd, J = 13.9, 7.9 Hz, 1H), 2.48 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.8 (d, J = 242.8 Hz), 145.8, 145.5, 144.4 (d, J = 2.2 Hz), 139.7, 136.4, 130.6 (d, J = 7.8 Hz), 130.2, 129.0, 128.0, 123.6, 125.1 (d, J = 8.2 Hz), 119.5, 116.2 (d, J = 22.4 Hz), 114.8 (d, J = 22.0 Hz), 61.9, 49.2, 36.7, 21.7; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{22}\text{FN}_2\text{O}_2\text{S}_2^+$ ($\text{M}+\text{H}^+$): 441.1101, found: 441.1090.



































































































































Table 1. Crystal data and structure refinement for **3s** (CCDC 1859862).

Identification code	ga_80710ea_a	
Empirical formula	C ₂₄ H ₂₄ N ₂ O ₂ S ₂	
Formula weight	436.57	
Temperature	296(2) K	
Wavelength	1.34138 Å	
Crystal system	Orthorhombic	
Space group	Pbca	
Unit cell dimensions	a = 18.532(2) Å	a = 90°.
	b = 11.0873(17) Å	b = 90°.
	c = 21.537(4) Å	g = 90°.
Volume	4425.2(11) Å ³	
Z	8	

Density (calculated)	1.311 Mg/m ³
Absorption coefficient	1.551 mm ⁻¹
F(000)	1840
Crystal size	0.480 x 0.450 x 0.100 mm ³
Theta range for data collection	4.131 to 58.989°.
Index ranges	-21<=h<=23, -11<=k<=14, -27<=l<=27
Reflections collected	26282
Independent reflections	4786 [R(int) = 0.0508]
Completeness to theta = 53.594°	99.2 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.805 and 0.503
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	4786 / 0 / 277
Goodness-of-fit on F ²	1.034
Final R indices [I>2sigma(I)]	R1 = 0.0549, wR2 = 0.1506
R indices (all data)	R1 = 0.0585, wR2 = 0.1569
Extinction coefficient	n/a
Largest diff. peak and hole	1.155 and -0.477 e.Å ⁻³